The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists

Monges, Geneviève; Bisot-Locard, S.; Blay, Jean‐Yves; Bouvier, Anne–Marie; Urbieta, M.; Coindre, Jean‐Michel; Scoazec, Jean‐Yves

doi:10.1684/bdc.2010.1041

Cited by 50 publications

(33 citation statements)

References 19 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results showed the crude incidence of GISTs between 2004 and 2008 was 2.11 per 100,000 and the age-standardized incidence was 1.28 per 100,000. Compared with previous studies in Europe and North America, the crude incidence in China (2.11 per 100,000) was higher than that in Canada (0.51–0.96 per 100,000), France (0.85–1.0 per 100,000), Italy (1.42 per 100,000), and Sweden (1.45 per 100,000) [8, 11, 14, 22]. Moreover, the world age-standardized incidence in our study (1.28 per 100,000) was also higher than that in Iceland (1.1 per 100,000), Italy (0.66 per 100,000), and Spain (0.65 per 100,000) [9, 11, 12].…”

Section: Discussioncontrasting

confidence: 75%

See 1 more Smart Citation

Incidence and Survival Analysis of Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study from 2001 to 2010

Zheng

et al. 2014

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Objectives. A population-based study was undertaken to investigate the epidemiological features of gastrointestinal stromal tumors (GISTs) in Shanghai, especially the incidence and the preliminary exploration of survival. Methods. A total of 1923 patients with GISTs diagnosed from 2001 to 2010 in Shanghai were reviewed. The annual incidence and overall survival of GISTs were calculated; Cox proportional hazards' regression was used to analyze several prognostic factors. Results. The average crude incidence of GISTs was 2.11 per 100,000 between 2004 and 2008, and the age-standardized incidence was 1.28 per 100,000. The incidence increased gradually from 2004 to 2008. In addition, 57% of cases had GIST in the stomach and 33% in the intestine. The 5-year overall survival of GISTs was 86.98%. The Cox regression analysis showed older age (≥65 yr versus <40 yr, HR = 5.085; (40, 65) yr versus <40 yr, HR = 1.975), male gender (HR = 1.474), and tumor locations (intestinal versus stomach, HR = 1.609) were predictors of its mortality. Conclusion. GISTs, mainly occurring in the stomach, are more common in elderly population, with an increasing incidence from 2004 to 2008. Older age, male gender, and tumor locations are risk factors for its mortality.

show abstract

Section: Discussioncontrasting

confidence: 75%

“…Currently, on the basis of several population-based studies, the annual incidence of GIST ranges between 1 and 2 per 100,000 [8–14]. Complete surgical resection has been the treatment of choice for localized resectable GISTs [15].…”

Section: Introductionmentioning

confidence: 99%

Incidence and Survival Analysis of Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study from 2001 to 2010

Zheng

et al. 2014

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…reported that the incidence of GISTs in Korea was approximately 1.6-2.2 per 100,000 [19]. Studies from Europe and North America reported a GIST incidence of 1.45 per 100,000 in Sweden [20], 0.65-0.90 per 100,000 in Spain [21], 0.6-1.9 per 100,000 in Norway [22], 0.66 in Italy [23], 0.85-1.00 per 100,000 in France [24], 0.9 per 100,000 in Canada [25], 1.32 per 100,000 in United Kingdom [26], and 0.7 per 100,000 in USA [17]. Given the different study time periods and the lack of confirmation by KIT immunohistochemical staining in some studies, it is difficult to compare the incidence rates of GISTs across different countries; however, the published literature to date showed that the incidence rates of GISTs in different countries appeared to fall in a similar range.…”

Section: Discussionmentioning

confidence: 99%

The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998–2008: a nation-wide cancer registry-based study

et al. 2014

View full text Add to dashboard Cite

BackgroundTo investigate the incidence of gastrointestinal stromal tumors (GISTs) in Taiwan and the impact of imatinib on the overall survival (OS) of GIST patients.MethodsGISTs were identified from the Taiwan Cancer Registry (TCR) from 1998 to 2008. The age-adjusted incidence rates and the observed OS rates were calculated. Cox proportional hazards models were applied to examine the mortality risk in three time periods (1998–2001, 2002–2004, 2005–2008) according to the application and availability of imatinib.ResultsFrom 1998 to 2008, 2,986 GISTs were diagnosed in Taiwan. The incidence increased from 1.13 per 100,000 in 1998 to 1.97 per 100,000 in 2008. The most common sites were stomach (47-59%), small intestine (31-38%), and colon/rectum (6-9%). The 5-year observed OS was 66.5% (60.3% for men, 74.2% for women, P < .0001). GISTs in the stomach had a better 5-year observed OS (69.4%) than those in the small intestine (65.1%) (P < .0001). The outcome of GIST improved significantly after the more widespread use of imatinib; the 5-year observed OS increased from 58.9% during 1998–2001 to 70.2% during 2005–2008 (P < .0001). Younger age, female sex, stomach location, and later diagnostic years were independent predictors of a better survival.ConclusionsThe incidence of GIST has been increasing in Taiwan, partially due to the advancement of diagnostic technology/method and the increased awareness by physicians. The outcome of GIST has improved significantly with the availability and the wider use of imatinib.

show abstract

“…Symptoms are highly dependent on the size and location of the tumor. Symptomatic patients are as low as 47–69% at the diagnosis, 1,2) and most symptoms are non-specific. Besides, in 20–30% of cases, patients present features of metastasis upon first diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…1–3) The prognosis of the tumor was dismal before the discovery of imatinib mesylate (Glivec ® , Novartis Pharma AG, Basel, Switzerland), a novel receptor tyrosine kinase inhibitor, with occasional metastasis to the liver and peritoneum. However, metastasis of the tumor to the brain is extremely rare, with only a few cases hitherto were reported.…”

Section: Introductionmentioning

confidence: 99%

Sunitinib Treatment for Multiple Brain Metastases from Jejunal Gastrointestinal Stromal Tumor: Case Report

Takeuchi¹,

Koike

Fujita³

et al. 2014

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are rare malignant tumors and only a few reported cases of brain metastases can be found. Introduction of a new molecular targeted agent, imatinib mesylate in the last decade has dramatically changed the treatment strategy and prognosis. However, imatinib is usually ineffective for brain metastasis from GISTs. The authors present the case of multiple brain metastases from jejunal GIST. The brain metastasis in the right prefrontal gyrus was detected 20 months after resection of the primary lesion when left hemiparesis began although the patient was on imatinib. Then the patient began taking sunitinib instead of imatinib, and the lesion shrunk and the symptom improved. However, after the dose reduction due to side effects, a new brain metastasis was found and this time, stereotactic radiation was effectively done. Sunitinib is one of the promising receptor tyrosine kinase inhibitors used for metastatic renal cell carcinomas or imatinib-refractory GISTs. Sunitinib is thought to penetrate bloodbrain barrier, and recent reports indicate effectiveness to brain metastasis. To the authors' knowledge, this is the fi rst report of brain metastases from jejunal GIST responding to sunitinib therapy.

show abstract

The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists

Cited by 50 publications

References 19 publications

Incidence and Survival Analysis of Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study from 2001 to 2010

Incidence and Survival Analysis of Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study from 2001 to 2010

The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998–2008: a nation-wide cancer registry-based study

Sunitinib Treatment for Multiple Brain Metastases from Jejunal Gastrointestinal Stromal Tumor: Case Report

Contact Info

Product

Resources

About